Innate Immune Activation in Autoimmune Myopathy

自身免疫性肌病的先天免疫激活

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT The idiopathic inflammatory myopathies (IIMs) represent a group of systemic autoimmune disorders in which muscle and extra-muscular organs are targeted for immune-mediated destruction. We have previously established a model of histidyl-tRNA synthetase (HRS)-induced myositis that involves MyD88-dependent innate immune signaling pathways featuring Toll-like receptors 2 and 4 (TLR2, TLR4). Given the prominent role of these TLRs in our model of HRS-induced myositis, we hypothesize that heightened activation of the downstream transcription regulator NF-κB is ultimately responsible for various inflammatory cascades as well as non-immune pathways promoting muscle dysfunction in this system—effectively linking HRS-induced myositis/IIM with other disorders (including muscular dystrophy as well as sepsis- and trauma/ischemia- induced myopathies) in which NF-κB dysregulation contributes to muscle inflammation, muscle degeneration, and impaired regenerative potential. Through a series of in vitro culture systems and in vivo immunization strategies involving knockout mice lacking critical components of MyD88-dependent signaling pathways, we will systematically examine the impact of HRS-induced TLR signaling and NF-κB activation on T cell migration, T cell activation, and muscle weakness. While Specific Aim 1 will focus on HRS-induced changes in T cell function and TLR-mediated activation of vascular endothelium (leading to lymphocytic infiltration of target organs), Specific Aim 2 will define direct and indirect pathways of HRS-induced NF-κB activation in muscle tissue through in vitro myoblast stimulation assays as well as additional immunization studies focusing on correlations between muscle inflammation, NF-κB activation, and in vivo/ex vivo parameters of muscle weakness. Complementary in vivo assessment tools including MRI and the use of NF-κB-luciferase transgenic mice will further define the relationship between HRS-mediated NF-κB activation and muscle dysfunction, providing the foundation for experimental trials of comparative NF-κB inhibition in Specific Aim 3. Collectively, these studies will elucidate the contribution of innate immunity to the pathogenesis of IIM, supplementing more traditional paradigms of antigen-specific, adaptive immune recognition and identifying therapeutic targets that are potentially relevant to a range of human inflammatory muscle diseases.
项目摘要/摘要 特发性炎症性肌病(IIM)代表一组全身性自身免疫性疾病 肌肉和肌肉外器官是免疫中介破坏的目标。我们之前已经 建立组氨酰-tRNA合成酶(HRS)诱导的涉及MyD88依赖的肌炎模型 以Toll样受体2和4(TLR2、TLR4)为特征的先天免疫信号通路。考虑到突出的 这些TLRs在我们的HRS诱导的肌炎模型中的作用,我们假设 下游转录调节因子NF-κB也是各种炎症级联反应的最终责任者 作为非免疫途径促进该系统中的肌肉功能障碍-有效地连接HRS诱导的 肌炎/IIM合并其他疾病(包括肌营养不良和脓毒症-以及创伤/缺血- 诱导的肌病),在这种情况下,核因子-κB的失调导致肌肉炎症、肌肉变性、 以及受损的再生潜能。通过一系列体外培养系统和体内免疫 涉及缺乏MyD88依赖的信号通路关键组件的基因敲除小鼠的策略,我们 将系统地研究HRS诱导的TLR信号和NF-κB激活对T细胞迁移的影响, T细胞激活,肌肉无力。而特定目标1将专注于HRS诱导的T细胞变化 血管内皮细胞的功能和TLR介导的激活(导致靶细胞的淋巴细胞渗透) 器官),特异性目标2将定义高铁诱导的肌肉中NF-κB激活的直接和间接途径 组织通过体外成肌细胞刺激分析以及其他免疫研究,重点是 肌肉炎症、核因子-κB激活与肌肉体内外参数的相关性 软弱。补充体内评估工具,包括核磁共振和使用核转录因子-κB-荧光素酶转基因 小鼠将进一步确定HRS介导的NF-κB激活和肌肉功能障碍之间的关系, 为针对特定目标的比较核转录因子-κB抑制的实验试验提供基础。 这些研究将阐明先天免疫在IIM发病机制中的作用,补充更多 抗原特异性、适应性免疫识别和识别治疗靶点的传统范例 可能与一系列人类炎症性肌肉疾病有关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANA P ASCHERMAN其他文献

DANA P ASCHERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANA P ASCHERMAN', 18)}}的其他基金

Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease
评估风湿性疾病中 SARS-CoV-2 疫苗接种的临床和免疫学后果
  • 批准号:
    10532784
  • 财政年份:
    2021
  • 资助金额:
    $ 38万
  • 项目类别:
Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease
评估风湿性疾病中 SARS-CoV-2 疫苗接种的临床和免疫学后果
  • 批准号:
    10362978
  • 财政年份:
    2021
  • 资助金额:
    $ 38万
  • 项目类别:
Innate Immune Activation in Autoimmune Myopathy
自身免疫性肌病的先天免疫激活
  • 批准号:
    9926715
  • 财政年份:
    2017
  • 资助金额:
    $ 38万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8278446
  • 财政年份:
    2011
  • 资助金额:
    $ 38万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8397571
  • 财政年份:
    2011
  • 资助金额:
    $ 38万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8142414
  • 财政年份:
    2011
  • 资助金额:
    $ 38万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8696779
  • 财政年份:
    2011
  • 资助金额:
    $ 38万
  • 项目类别:
Functional impact of dendritic cell phenotype in a mouse model of myositis
树突状细胞表型对肌炎小鼠模型的功能影响
  • 批准号:
    7659076
  • 财政年份:
    2009
  • 资助金额:
    $ 38万
  • 项目类别:
Functional impact of dendritic cell phenotype in a mouse model of myositis
树突状细胞表型对肌炎小鼠模型的功能影响
  • 批准号:
    8188933
  • 财政年份:
    2009
  • 资助金额:
    $ 38万
  • 项目类别:
Functional impact of dendritic cell phenotype in a mouse model of myositis
树突状细胞表型对肌炎小鼠模型的功能影响
  • 批准号:
    7799180
  • 财政年份:
    2009
  • 资助金额:
    $ 38万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了